TEAM
CURRENT MEMBERS
Postdoctoral researchers
Animal-free food safety evaluation
To be completed in 2024
Promoter: Mathieu Vinken
Miloš Mihajlović
Development of a new liver-based in vitro system to detect cholestatic chemicals
To be completed in 2026
Promoter: Mathieu Vinken
Julen Sanz Serrano
In vitro testing of new inhibitors of Cx43 hemichannels and Panx1 channels
To be completed in 2024
Promoter: Mathieu Vinken
Andrés Tabernilla
In vivo testing of new inhibitors of Cx43 hemichannels and Panx1 channels
To be completed in 2024
Promoter: Mathieu Vinken
Prashant Kadam
Doctoral researchers
Risk assessment of chemical mixtures: liver toxicity as a case study
To be defended in 2026
Promoters: Mathieu Vinken, Nynke Kramer, Jochem Louisse
Ellen Callewaert
Development of a mechanism-based and artificial intelligence-fed in vitro test platform to predict chemical-induced cholestatic liver injury
To be defended in 2027
Promoters: Mathieu Vinken, Julen Sanz Serrano
Annika Drees
.jpg)
Optimization of Panx1 nanobodies towards clinical treatment of inflammatory liver disease
To be defended in 2027
Promoters: Mathieu Vinken, Raf Van Campenhout
Daan Peeters
Effects of microplastics on liver in vitro and in vivo
To be defended in 2025
Promoters: Mathieu Vinken, Lindsey Devisscher
Sybren De Boever
Effects of food supplements on liver in vitro and in vivo
To be defended in 2025
Promoters: Mathieu Vinken, Lindsey Devisscher
Amy Maerten
Development of new inhibitors of Cx43 hemichannels and Panx1 channels as novel therapeutics for the treatment of liver disease
To be defended in 2022
Promoters: Mathieu Vinken, Nick Devoogdt, Serge Muyldermans
Co-promotor: Timo De Groof
Raf Van Campenhout
In vitro detection of steatotic chemicals
To be defended in 2025
Promoters: Mathieu Vinken, Tamara Vanhaecke
Co-promotor: Joery De Kock
Anouk Verhoeven
In vitro testing of the hepatotoxic/hepatoprotective potential of herbal medicines and dietary supplements
To be defended in 2026
Promoters: Mathieu Vinken, Hilmi Orhan
Co-promotors: Kristiaan Demeyer, Andrés Tabernilla
Batuhan Yildiz
Role of cellular communication mediated by pannexin1 channels in non-alcoholic fatty liver disease induced by microgravity and radiation
To be defended in 2027
Promoter: Mathieu Vinken
Co-promotors: Bjorn Baselet, Kevin Tabury
Ben Cools
Technicians
Fien Haenen
Arne Loosen
Project manager
Julia Dominika Zajac
FORMER TEAM MEMBERS
Dr. Alanah Pieters
Dr. Elif Ince Ergüç
Dr. Vânia Vilas-Boas
M. Sci. Emma Arnesdotter
M. Sci. Sara Crespo-Yanguas
M. Sci. Kaat Leroy
Pharm. Eva Gijbels
Pharm. Michaël Maes
Pharm. Joost Willebrords
Miss Ana Rita Coelho Gomes
Miss Dinja De Win
Miss Tâmara Prandini
Miss Tineke Vanhalewyn
Miss Manon Wery
FINISHED POSTDOCTORAL PROJECTS
Role of connexin and pannexin (hemi)channels in liver cancer
Tereza Cristina da Silva: completed 31/03/2017
Promoters: Mathieu Vinken, Bruno Cogliati
Role of connexin and pannexin (hemi)channels in hepatitis
Isabel Veloso Alves Pereira: completed 31/03/2017
Promoters: Mathieu Vinken, Bruno Cogliati
Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury
Vânia Vilas-Boas: completed 31/12/2020
Promoter: Mathieu Vinken
Role of connexin and pannexin (hemi)channels in cholestasis
Alanah Pieters: completed 31/01/2022
Promoter: Mathieu Vinken
Identification of natural inhibitors of pannexin channels
Elif Ince Ergüç: completed 31/01/2023
Promoter: Mathieu Vinken
In vitro and in silico prediction of chemical-induced liver toxicity
Jian Jiang: completed 15/04/2023
Promoter: Mathieu Vinken
Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury
Bruna dos Santos Rodrigues: completed 30/09/2023
Promoter: Mathieu Vinken
FINISHED DOCTORAL PROJECTS
Evaluation of carcinogen-modified global gene expression profiles in liver-based in vitro models with focus on primary hepatocyte cultures
Tatyana Doktorova: defended 16/03/2012
Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers
Development of a differentiated hepatic in vitro system for long-term pharmaco-toxicological studies based on (epi)genetic modification of primary hepatocytes
Eva Ramboer: defended 15/10/2015
Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers
The role of connexins, pannexins and their channels in acute liver failure
Michaël Maes: defended 17/10/2017
Promoters: Mathieu Vinken, Bruno Cogliati
The role of connexins, pannexins and their channels in non-alcoholic steatohepatitis
Joost Willebrords: defended 29/01/2018
Promoters: Mathieu Vinken, Bruno Cogliati
The role of connexins, pannexins and their channels in liver fibrosis
Sara Crespo Yanguas: defended 25/10/2018
Promoters: Mathieu Vinken, Bruno Cogliati
Connexin43 hemichannels as druggable targets for future anti-seizure medication
Laura Walrave: defended 24/01/2019
Promoter: Ilse Smolders
Co-promoters: Mathieu Vinken, Luc Leybaert
Modelling and prediction of chemical-induced human cholestatic liver injury: a mechanistic approach
Eva Gijbels: defended 01/12/2021
Promoters: Mathieu Vinken, Lindsey Devisscher
Co-promoter: Tamara Vanhaecke
Towards next generation risk assessment of chemicals: liver toxicity as a case study
Emma Arnesdotter: defended 19/05/2022
Promoters: Mathieu Vinken, Tamara Vanhaecke
Role of connexins, pannexins and their channels in liver cancer
Kaat Leroy: defended 31/01/2023
Promoters: Mathieu Vinken, Bruno Cogliati
Identification, development and in vitro testing of pannexin1 channel inhibitors
Anne Caufriez: defended 03/10/2023
Promoters: Mathieu Vinken, Steven Ballet
Role of connexins and their channels in cholestasis
Axelle Cooreman: defended 11/10/2023
Promoters: Mathieu Vinken, Pieter Annaert
© 2023 by InVitroTox Consulting.
Proudly created using Wix.com
